2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-135425R
    10,12-Tricosadiynoic acid (Standard) 66990-30-5
    10,12-Tricosadiynoic acid (Standard) is the analytical standard of 10,12-Tricosadiynoic acid. This product is intended for research and analytical applications. 10,12-Tricosadiynoic acid is a highly specific, selective, high affinity and orally active acyl-CoA oxidase-1 (ACOX1) inhibitor. 10,12-Tricosadiynoic acid can treat high fat diet- or obesity-induced metabolic diseases by improving mitochondrial lipid and ROS metabolism[1]. 10,12-Tricosadiynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    10,12-Tricosadiynoic acid (Standard)
  • HY-135586R
    Raloxifene N-Oxide (Standard) 195454-31-0
    Raloxifene N-Oxide (Standard) is the analytical standard of Raloxifene N-Oxide. This product is intended for research and analytical applications. Raloxifene N-Oxide is a Raloxifene oxidative degradation product.
    Raloxifene N-Oxide (Standard)
  • HY-135670A
    β-glycosidase-IN-1 176485-27-1 98%
    β-glycosidase-IN-1 (Compound 33) is a piperidine derivative and a β-glycosidase inhibitor. β-glycosidase-IN-1 has hypoglycemic activity.
    β-glycosidase-IN-1
  • HY-135670B
    Glycosidase-IN-2 476310-39-1 98%
    Glycosidase-IN-2 (Compound 20) is an azasugar class of glycosidase inhibitor. Glycosidase-IN-2 has hypoglycemic activity.
    Glycosidase-IN-2
  • HY-135772R
    12-Ketodeoxycholic acid (Standard) 5130-29-0
    12-Ketodeoxycholic acid (Standard) is the analytical standard of 12-Ketodeoxycholic acid. This product is intended for research and analytical applications. 12-Ketodeoxycholic acid (12-Ketolithocholic acid) is a bile acid, metabolite from kidney. 12-Ketodeoxycholic acid can be a detectable marker for evidence of kidney injury[1]
    12-Ketodeoxycholic acid (Standard)
  • HY-136438R
    Toltrazuril sulfoxide (Standard) 69004-15-5
    Toltrazuril sulfoxide (Standard) is the analytical standard of Toltrazuril sulfoxide. This product is intended for research and analytical applications. Toltrazuril sulfoxide is a short-lived intermediary metabolite of Toltrazuril (HY-B0175), and then can be metabolized to the reactive toltrazuril sulfone (TZR-SO2) in vivo. Toltrazuril is an antiprotozoal agent that acts upon Coccidia parasites.
    Toltrazuril sulfoxide (Standard)
  • HY-137390A
    (3S,5R)-Fluvastatin potassium 1009811-63-5 98%
    (3S,5R)-Fluvastatin (potassium) is a synthetic hypolipidemic drug that inhibits HMG-CoA reductase activity. (3S,5R)-Fluvastatin (potassium) has similar antioxidative effects on copper ion-induced LDL oxidation compared to its 3R,5S enantiomer. (3S,5R)-Fluvastatin (potassium) and its metabolites demonstrate a potential to exhibit anti-atherosclerotic effects through their antioxidative activities. (3S,5R)-Fluvastatin (potassium) is clinically utilized as part of a racemic mixture for reducing plasma cholesterol levels.
    (3S,5R)-Fluvastatin potassium
  • HY-137593A
    N6-Etheno-nicotinamide dinucleotide phosphate trisodium 98%
    N6-Etheno-nicotinamide dinucleotide phosphate (ε-NADP+) trisodium, a structural analogue of the NADP(+), is a maize malic enzyme inhibitor with a Ki of 1.01 μM.
    N6-Etheno-nicotinamide dinucleotide phosphate trisodium
  • HY-137638A
    Sp-5,6-DCl-cBIMPS sodium 142439-96-1 98%
    Sp-5,6-DCl-cBIMPS sodium is a potent and specific cAMP-dependent protein kinases (cAMP-PK) activator. Sp-5,6-DCl-cBIMPS sodium stimulates insulin release. Sp-5,6-DCl-cBIMPS sodium inhibits U-46619 (HY-108566)-induced activation of Rho, Gq and G12/G13 in platelets.
    Sp-5,6-DCl-cBIMPS sodium
  • HY-137675A
    isoGDP trisodium 98%
    isoGDP (trisodium) is a GDP isomer. isoGDP (trisodium) is a phosphorylated form of crotonoside. isoGDP (trisodium) is an inhibitor of mitochondrial ATPase with an IC50 of 3 μM.
    isoGDP trisodium
  • HY-13777AR
    Zoledronic acid monohydrate (Standard) 165800-06-6
    Zoledronic acid (monohydrate) (Standard) is the analytical standard of Zoledronic acid (monohydrate). This product is intended for research and analytical applications. Zoledronic acid monohydrate (Zoledronate monohydrate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic acid monohydrate inhibits the differentiation and apoptosis of osteoclasts. Zoledronic acid monohydrate also has anti-cancer effects.
    Zoledronic acid monohydrate (Standard)
  • HY-137813S
    PERK-IN-4-d3 98%
    PERK-IN-4-d3 is the deuterium labeled PERK-IN-4. PERK-IN-4 is a potent and selective PERK (protein kinase R (PKR)-like endoplasmic reticulum kinase) inhibitor with an IC50 of 0.3 nM. PERK is activated in response to a variety of endoplasmic reticulum stresses implicated in numerous disease states.
    PERK-IN-4-d3
  • HY-138119A
    γ-Glutamylserine TFA 98%
    γ-Glutamylserine TFA (γ-Glu-Ser TFA) is a calcium receptor activator. γ-Glutamylserine TFA can be used for Parkinson's disease research, as well as diabetes or obesity study.
    γ-Glutamylserine TFA
  • HY-138166R
    Rosuvastatin lactone (Standard) 503610-43-3
    Rosuvastatin lactone (Standard) is the analytical standard of Rosuvastatin lactone. This product is intended for research and analytical applications. Rosuvastatin lactone is a metabolite of Rosuvastatin (HY-17504A) (HMG-CoA inhibitor).
    Rosuvastatin lactone (Standard)
  • HY-139058R
    23-epi-26-Deoxyactein (Standard) 501938-01-8
    23-epi-26-Deoxyactein (Standard) is the analytical standard of 23-epi-26-Deoxyactein. This product is intended for research and analytical applications. 23-epi-26-Deoxyactein is a natural and orally active anti-obesity and anti-cancer compound.
    23-epi-26-Deoxyactein (Standard)
  • HY-14153AS
    Tegaserod-13C,d3 maleate 98%
    Tegaserod-13C,d3 (maleate) is the 13C- and deuterium labeled Tegaserod (maleate). Tegaserod maleate is a selective 5-HT4 receptor partial agonist and a 5-HT2B receptor antagonist. Tegaserod maleate exhibits a promotile effect throughout the gastrointestinal (GI) tract.
    Tegaserod-13C,d3 maleate
  • HY-141578R
    C18:1-Ceramide (Standard) 5966-28-9
    C18:1-Ceramide (Standard) is the analytical standard of C18:1-Ceramide. This product is intended for research and analytical applications. C18:1-Ceramide is a ceramide subspecies. C18:1-Ceramide can be used in the study of type 2 diabetes
    C18:1-Ceramide (Standard)
  • HY-142105R
    2-Ethyl-2-hydroxybutanoic acid (Standard) 3639-21-2
    Eliglustat (Standard) is the analytical standard of Eliglustat. This product is intended for research and analytical applications. Eliglustat is an specific, potent and orally active glucocerebroside synthase inhibitor with an IC50 of 24 nM.
    2-Ethyl-2-hydroxybutanoic acid (Standard)
  • HY-14275S1
    Verapamil-d7 100578-79-8 98%
    Verapamil-d7 is the deuterium labeled Verapamil (HY-14275). Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research.
    Verapamil-d7
  • HY-14291S1
    Vildagliptin-d7 1133208-42-0 98%
    Vildagliptin-d7 is deuterium labeled Vildagliptin. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity.
    Vildagliptin-d7
Cat. No. Product Name / Synonyms Application Reactivity